TransMedics (TMDX) stock jumps 7% premarket after earnings, 2026 revenue outlook
TransMedics Group shares jumped 7.3% premarket to $147.88 after posting Q4 revenue of $160.8 million, up 32%, and setting a 2026 revenue forecast of $727–$757 million. Net income for the quarter reached $105.4 million, boosted by an $83.8 million tax benefit. Adjusted earnings were 57 cents per share, topping analyst estimates. Gross margin slipped to 58% as clinical service and freight costs rose.